S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:SYBX

Synlogic (SYBX) Stock Forecast, Price & News

$2.81
-0.35 (-11.08%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.55
$3.15
50-Day Range
$2.81
$47.40
52-Week Range
$2.55
$20.25
Volume
145,063 shs
Average Volume
19,043 shs
Market Capitalization
$12.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.00

Synlogic MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,280.8% Upside
$95.00 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Synlogic in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($13.74) to ($13.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

492nd out of 970 stocks

Pharmaceutical Preparations Industry

229th out of 451 stocks


SYBX stock logo

About Synlogic (NASDAQ:SYBX) Stock

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

SYBX Price History

SYBX Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Synlogic, Inc.: Synlogic Announces Reverse Stock Split
Synlogic Announces Reverse Stock Split
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Synlogic (SYBX) Receives a Buy from H.C. Wainwright
Expert Ratings for Synlogic
The Latest Analyst Ratings for Synlogic
H.C. Wainwright Remains a Buy on Synlogic (SYBX)
SVB Securities Keeps Their Buy Rating on Synlogic (SYBX)
What 6 Analyst Ratings Have To Say About Synlogic
See More Headlines
Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

SYBX Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYBX
Employees
72
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$95.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+3,280.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-66,150,000.00
Net Margins
-6,573.82%
Pretax Margin
-6,572.91%

Debt

Sales & Book Value

Annual Sales
$1.18 million
Book Value
$17.56 per share

Miscellaneous

Free Float
4,209,000
Market Cap
$12.87 million
Optionable
Not Optionable
Beta
0.96

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Aoife M. Brennan BAO (Age 47)
    BCh, M.D., MB, MMSc, Pres, CEO & Director
    Comp: $872.09k
  • Mr. Michael Jensen
    Chief Financial Officer
  • Mr. Antoine Awad (Age 43)
    Chief Operating Officer
    Comp: $566.55k
  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. James J. Collins Ph.D. (Age 57)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Brendan St. Amant
    Gen. Counsel & Corp. Sec.
  • Mr. Ajay Munshi
    VP of Corp. Devel.
  • Mr. Adam Thomas
    Chief People Officer
  • Dr. Caroline B. Kurtz Ph.D.
    Chief Devel. Officer
  • Ms. Molly Harper (Age 46)
    Chief Bus. Officer













SYBX Stock - Frequently Asked Questions

Should I buy or sell Synlogic stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYBX shares.
View SYBX analyst ratings
or view top-rated stocks.

What is Synlogic's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price objectives for Synlogic's stock. Their SYBX share price forecasts range from $75.00 to $120.00. On average, they anticipate the company's share price to reach $95.00 in the next twelve months. This suggests a possible upside of 3,280.8% from the stock's current price.
View analysts price targets for SYBX
or view top-rated stocks among Wall Street analysts.

How have SYBX shares performed in 2023?

Synlogic's stock was trading at $11.40 at the beginning of 2023. Since then, SYBX stock has decreased by 75.4% and is now trading at $2.81.
View the best growth stocks for 2023 here
.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 301,400 shares, an increase of 56.7% from the August 31st total of 192,400 shares. Based on an average daily volume of 202,700 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.7% of the shares of the company are short sold.
View Synlogic's Short Interest
.

When is Synlogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SYBX earnings forecast
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) released its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($3.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.90) by $0.75. The biotechnology company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.18 million. Synlogic had a negative net margin of 6,573.82% and a negative trailing twelve-month return on equity of 85.18%.

When did Synlogic's stock split?

Synlogic's stock reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Synlogic own?
What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $2.81.

How much money does Synlogic make?

Synlogic (NASDAQ:SYBX) has a market capitalization of $12.87 million and generates $1.18 million in revenue each year. The biotechnology company earns $-66,150,000.00 in net income (profit) each year or ($13.9430) on an earnings per share basis.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for the company is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.

This page (NASDAQ:SYBX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -